超快速短效致幻剂治疗抑郁症的优势与挑战
本文综述5-甲氧基-N,N-二甲基色胺(5-MeO-DMT)和N,N-二甲基色胺(DMT)的临床药理学及其治疗抑郁症的潜在优势与挑战。小样本早期临床试验显示,15-30分钟的短干预安全且耐受良好,可在24小时内诱导抑郁症状显著改善并至少维持1周;长期疗效数据稀缺但提示治疗反应延长。未来挑战包括确定抗抑郁效应持续时间、维持策略、优化治疗实施参数及机制理解。
要点
- 5-MeO-DMT和DMT短干预(15-30分钟)在小样本早期试验中安全且耐受良好。
- 可在24小时内诱导抑郁症状显著改善,并至少维持1周。
- 长期疗效数据稀缺但提示治疗反应延长;需随机安慰剂对照试验重复验证。
核心结论
- 超快速短效致幻剂5-MeO-DMT和DMT的短干预在小样本早期试验中安全且耐受良好,可在24小时内显著改善抑郁症状并至少维持1周,但长期疗效数据稀缺,其接受度将取决于未来随机安慰剂对照试验对疗效重复、持续时间及维持的验证。
研究设计与样本
- 本文为综述,回顾5-MeO-DMT和DMT的临床药理学及其治疗抑郁症的潜在优势与挑战。
- 文中引用的早期临床试验为小样本研究,干预时长为15-30分钟。
主要发现
- 5-MeO-DMT和DMT对多种单胺受体和转运体显示亲和力,但主要对5-羟色胺(5HT)受体包括5HT1A和5HT2A显示亲和力。
- 小样本早期临床试验显示,5-MeO-DMT和DMT的短干预(15-30分钟)安全且耐受良好,可在24小时内诱导抑郁症状显著改善并至少维持1周。
- 长期疗效数据当前稀缺,但确实提示治疗反应延长。
关键数值与推荐
- 潜在优势包括灵活的单日给药方案、治疗疗效不依赖于整合治疗即可实现、以及临床实施简便。
- 未来挑战包括确定抗抑郁效应持续时间、制定维持抗抑郁反应的策略、优化治疗实施参数、以及理解临床反应的机制。
- 超快速短效致幻剂的接受度将取决于未来随机安慰剂对照试验,重点关注在大样本患者中重复验证抗抑郁疗效及其持续时间和维持。
临床怎么用
- 原文未据此给出推荐。
局限性
- 早期临床试验均为小样本研究。
- 长期疗效数据当前稀缺。
- 超快速短效致幻剂的接受度将取决于未来随机安慰剂对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but brief psychedelic intervention. The current paper reviews the clinical pharmacology of 5-MeO-DMT and DMT and their potential benefits and challenges in the treatment of depression. Both compounds display affinities for a variety of monoamine receptors and transporters, but mostly so for serotonergic (5HT) receptors, including 5HT1A and 5HT2A. Early clinical trials in small samples have shown that short interventions (15-30 min) with 5-MeO-DMT and DMT are safe and well tolerated and can induce marked improvement in symptoms of depression within 24 hours that sustain for at least 1 week. Data on long-term efficacy are currently scarce but do suggest a prolongation of the treatment response. Potential benefits of these treatments include flexible, single day dosing regimens, achievement of treatment efficacy independent from integrative therapy, and ease of clinical implementation. Future challenges include establishing the duration of the antidepressant effect and strategies on how to sustain the antidepressant response, optimization of treatment delivery parameters, and a mechanistic understanding of the clinical response. Acceptance of ultra-fast, short-acting psychedelics will depend on future randomized, placebo-controlled trials with a focus on replication, duration and maintenance of antidepressant efficacy in large patient samples.
引用
- Ramaekers JG, Reckweg JT, Mason NL, et al. Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression. Am J Psychiatry. 2025. PMID: 39741439. doi:10.1176/appi.ajp.20230890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。